학술논문
Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
Document Type
Article
Author
Adcock, Ian M; Azim, Adnam; Bellamy, Mary; Borg, Catherine; Bourne, Michelle; Connolly, Clare; Costello, Richard W; Corrigan, Chris J; Davies, Sarah; Davies, Gareth; Chung, Kian F; Gainsborough, Gabrielle; Grandison, Traceyanne; Hargadon, Beverley; Horn, Avril; Hudson, Val; Jackson, David; Johnston, Sebastian; Jones, Geraldine; McCourt, Paula; Nunez, Maria; Shaw, Dominic E; Smith, Katherine; Solis, Joel; Stone, Roisin; Yang, Freda; Heaney, Liam G ; Busby, John; Hanratty, Catherine E; Djukanovic, Ratko; Woodcock, Ashley; Walker, Samantha M; Hardman, Timothy C; Arron, Joseph R; Choy, David F; Bradding, Peter; Brightling, Christopher E; Chaudhuri, Rekha; Cowan, Douglas C; Mansur, Adel H; Fowler, Stephen J; Niven, Robert M; Howarth, Peter H; Lordan, James L; Menzies-Gow, Andrew; Harrison, Tim W; Robinson, Douglas S; Holweg, Cecile T J; Matthews, John G; Pavord, Ian D
Source
In The Lancet Respiratory Medicine January 2021 9(1):57-68
Subject
Language
ISSN
2213-2600